 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MINNEAPOLIS, March 26, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...

Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results

MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), ( Panbela ), a clinical stage company developing disruptive therapeutics for the treatment of patients...

Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024

Panbela Therapeutics regains compliance with Nasdaq...

Panbela Therapeutics regains compliance with Nasdaq

MINNEAPOLIS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), ( Panbela ), a clinical stage company developing disruptive therapeutics for the treatment of patients with...

Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements

Panbela Therapeutics (NASDAQ:PBLA  Get Free Report) and NeuroSense Therapeutics (NASDAQ:NRSN  Get Free Report) are both medical companies, but which is the better investment? We will...

Panbela Therapeutics (NASDAQ:PBLA) vs. NeuroSense Therapeutics (NASDAQ:NRSN) Head to Head Contrast

MINNEAPOLIS, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent...

Panbela Announces Closing of Approximately $9.0 Million Public Offering

Panbela Therapeutics announced acceptance of SBP-101 abstract for presentation and disclosed details of a public offering, expecting approximately $9.0 million in gross proceeds.
read more...

What's Going On With Panbela Therapeutics Stock Today?

MINNEAPOLIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...

Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)

MINNEAPOLIS, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent...

Panbela Announces Pricing of Approximately $9.0 Million Public Offering

Panbela Therapeutics, Processa Pharmaceuticals among healthcare movers...

Panbela Therapeutics, Processa Pharmaceuticals among healthcare movers

Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm’s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types. The company was founded by Michael T. Cullen, Jr. and Thomas X. Neenan on September 21, 2011 and is headquartered in Waconia, MN.

Volume (M)	78,607.00
52-Wk High	$0.95
52-Wk Low	$0.411

PBLA Panbela Therapeutics Inc

About

Feed

News

Earnings

Fundamentals